{"id":"folfox-folfiri-with-panitumumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Skin rash (panitumumab-related)"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFOX and FOLFIRI are standard chemotherapy regimens for colorectal cancer that damage DNA and inhibit cell division. Panitumumab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR) on cancer cells, blocking growth signals and preventing tumor progression. The combination leverages both direct cytotoxic effects and targeted growth inhibition to improve outcomes in colorectal cancer.","oneSentence":"This combination uses chemotherapy (FOLFOX or FOLFIRI) to kill rapidly dividing cancer cells, while panitumumab blocks EGFR signaling to prevent tumor growth and enhance chemotherapy efficacy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:15.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer, KRAS wild-type"}]},"trialDetails":[{"nctId":"NCT05863195","phase":"PHASE3","title":"Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-10-19","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8","enrollment":408},{"nctId":"NCT07318389","phase":"EARLY_PHASE1","title":"ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-06-10","conditions":"Dynamic Tumor Resistance, Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT06728072","phase":"PHASE2","title":"Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-03-07","conditions":"Colorectal Cancer, CRC","enrollment":97},{"nctId":"NCT04587128","phase":"PHASE2","title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-19","conditions":"Metastatic Colorectal Cancer","enrollment":34},{"nctId":"NCT07201519","phase":"PHASE2","title":"Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","status":"RECRUITING","sponsor":"Michael J Cavnar, MD","startDate":"2026-01-23","conditions":"Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma","enrollment":80},{"nctId":"NCT06332079","phase":"PHASE2","title":"Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-13","conditions":"Colorectal Cancer Metastatic","enrollment":4},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT03186326","phase":"PHASE2","title":"Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer","status":"COMPLETED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2018-04-24","conditions":"Metastatic Colorectal Cancer, MSI","enrollment":132},{"nctId":"NCT02162563","phase":"PHASE3","title":"Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2014-07","conditions":"Colorectal Cancer, Liver Metastases","enrollment":530},{"nctId":"NCT03635021","phase":"PHASE3","title":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2018-10-15","conditions":"Colorectal Cancer","enrollment":419},{"nctId":"NCT03043950","phase":"","title":"Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)","status":"COMPLETED","sponsor":"iOMEDICO AG","startDate":"2017-01-25","conditions":"Metastatic Colorectal Cancer, RAS Wild-type","enrollment":647},{"nctId":"NCT05862051","phase":"NA","title":"RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-12-14","conditions":"Colorectal Cancer, Oligometastatic Disease","enrollment":75},{"nctId":"NCT04276090","phase":"NA","title":"Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma","status":"TERMINATED","sponsor":"Michael J Cavnar, MD","startDate":"2020-05-01","conditions":"Bile Duct Neoplasms, Colorectal Neoplasms","enrollment":21},{"nctId":"NCT03251612","phase":"PHASE2","title":"Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2017-09-22","conditions":"Colorectal Cancer Metastatic","enrollment":90},{"nctId":"NCT03940131","phase":"PHASE2","title":"Re-challenge Therapy With Chemotherapy & Panitumumab in Metastatic Colorectal Cancer Patients Treated With an Anti-EGFR","status":"UNKNOWN","sponsor":"King Abdullah Medical City","startDate":"2020-06-10","conditions":"Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT00655499","phase":"PHASE2","title":"Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2008-06","conditions":"Colorectal Cancer","enrollment":65},{"nctId":"NCT03751176","phase":"PHASE2","title":"Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal","status":"UNKNOWN","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2018-11-08","conditions":"Colorectal Cancer Metastatic","enrollment":31},{"nctId":"NCT03311750","phase":"PHASE2","title":"Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer","status":"TERMINATED","sponsor":"Hellenic Cooperative Oncology Group","startDate":"2018-03-26","conditions":"Advanced Colorectal Cancer","enrollment":23},{"nctId":"NCT02015923","phase":"PHASE4","title":"Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2013-12","conditions":"Colonic Cancer, Unresectable Metastasis Originating in Colonic Cancer","enrollment":107},{"nctId":"NCT04735900","phase":"NA","title":"lead-in FOLICOLOR Trial: Following Therapy Response Through Liquid Biopsy in Metastatic Colorectal Cancer Patients","status":"UNKNOWN","sponsor":"University Hospital, Antwerp","startDate":"2020-09-14","conditions":"Metastatic Colorectal Cancer","enrollment":60},{"nctId":"NCT02624895","phase":"","title":"ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-12-30","conditions":"Metastatic Colorectal Cancer","enrollment":296},{"nctId":"NCT01260415","phase":"PHASE2","title":"A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2010-08","conditions":"Colorectal Cancer, Liver Metastases","enrollment":11},{"nctId":"NCT00115765","phase":"PHASE3","title":"PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-06-01","conditions":"Colorectal Cancer","enrollment":1053},{"nctId":"NCT00885885","phase":"PHASE2","title":"Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2009-05","conditions":"Colorectal Cancer","enrollment":80},{"nctId":"NCT00411450","phase":"PHASE2","title":"Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-11","conditions":"Colon Cancer, Colorectal Cancer, Rectal Cancer","enrollment":116},{"nctId":"NCT00101894","phase":"PHASE1","title":"Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-12","conditions":"Rectal Cancer, Colon Cancer","enrollment":119}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["- panitumumab","- irinotecan","- leucovorin","- 5-fluorouracil","- oxaliplatin"],"phase":"phase_3","status":"active","brandName":"FOLFOX/ FOLFIRI with panitumumab","genericName":"FOLFOX/ FOLFIRI with panitumumab","companyName":"Dutch Colorectal Cancer Group","companyId":"dutch-colorectal-cancer-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses chemotherapy (FOLFOX or FOLFIRI) to kill rapidly dividing cancer cells, while panitumumab blocks EGFR signaling to prevent tumor growth and enhance chemotherapy efficacy. Used for Metastatic colorectal cancer, KRAS wild-type.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}